1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Cathepsin
  4. Cathepsin L Isoform
  5. Cathepsin L Inhibitor

Cathepsin L Inhibitor

Cathepsin L Inhibitors (20):

Cat. No. Product Name Effect Purity
  • HY-128140
    Z-FY-CHO
    Inhibitor
    Z-FY-CHO (Z-Phe-Tyr-CHO) is a potent and specific cathepsin L (CTSL) inhibitor.
  • HY-103353
    SID 26681509
    Inhibitor 98.70%
    SID 26681509 is a potent, reversible, competitive, and selective inhibitor of human cathepsin L with an IC50 of 56 nM. SID 26681509 inhibits in vitro propagation of malaria parasite Plasmodium falciparum and inhibits Leishmania major with IC50s of 15.4 μM and 12.5 μM, respectively. SID 26681509 shows no inhibitory activity against cathepsin G.
  • HY-P0109A
    Z-FA-FMK
    Inhibitor 99.14%
    Z-FA-FMK ((1S)-Z-FA-FMK) is a potent Cathepsin B and L inhibitor. Z-FA-FMK blocks the induction of DEVDase activity, DNA fragmentation, and externalization of phosphatidylserine by selective synthetic retinoid-related molecules (RRMs). Z-FA-FMK inhibits apoptosis. Z-FA-FMK inhibits caspase activity and selectively inhibits recombinant effector caspases 2, -3, -6, and -7. Z-FA-FMK is a viral inhibitor. Z-FA-FMK inhibits reovirus replication in a susceptible host.
  • HY-15100
    Balicatib
    Inhibitor 98.00%
    Balicatib (AAE581) is a potent, orally active and selective cathepsin K inhibitor with IC50 values of 22, 61, 48, 2900 nM for cathepsin K, cathepsin B, cathepsin L, cathepsin S, respectively. Balicatib inhibits bone turnover, decreases bone formation rates. Balicatib has the potential for the research of osteoporosis.
  • HY-161245
    FGA146
    Inhibitor
    FGA146 is a dual, selective inhibitor for Mpro and human Cathepsin L, with Kis of 2.19 μM, 0.96 μM and 0.87 μM, for Mal-Mpro, pET21-Mpro and Cathepsin L, respectively. FGA146 reveals an antiviral activity against SARS-CoV-2.
  • HY-163389
    Mpro/Cathepsin L-IN-1
    Inhibitor
    Mpro/Cathepsin L-IN-1 (Compound 4d) is a SARS-CoV-2 Mpro/hCatL inhibitor, with Kis of 5.54 μM and 0.701 μM respectively.
  • HY-115733
    Cathepsin L-IN-2
    Inhibitor 98.27%
    Cathepsin L-IN-2 (Z-Phe-Phe-FMK) is a potent and irreversible cathepsin L and cathepsin B inhibitor.
  • HY-128971
    LHVS
    Inhibitor 99.87%
    LHVS is a potent, non-selective, irreversible, cell-permeable cysteine protease and cathepsin inhibitor. LHVS decreases actin ring formation. LHVS inhibits T. gondii invasion with an IC50 of 10 μM.
  • HY-10294
    Relacatib
    Inhibitor 99.99%
    Relacatib (SB-462795) is a novel, potent, and orally active inhibitor of human cathepsins K, L, and V with Ki values of 41 pM, 68 pM, and 53 pM, respectively. Relacatib inhibits endogenous cathepsin K in situ in human osteoclasts and human osteoclast-mediated bone resorption with IC50 values of 45 nM and 70 nM, respectively. Relacatib inhibits bone resorption in vitro in human tissue as well as in cynomolgus monkeys in vivo.
  • HY-N4289
    3-Epiursolic Acid
    Inhibitor 99.49%
    3-Epiursolic Acid is a triterpenoid that can be isolated from Eriobotrya japonica, acts as a competitive inhibitor of cathepsin L (IC50, 6.5 μM; Ki, 19.5 μM), with no obvious effect on cathepsin B.
  • HY-N2905
    Aurantiamide acetate
    Inhibitor 99.60%
    Aurantiamide acetate (TMC-58A) is a selective and orally active cathepsin inhibitor isolated from Portulaca oleracea L. Aurantiamide acetate has anti-inflammatory activities and can be used for the study of  inflammatory diseases.
  • HY-138208
    Z-Phe-Tyr(tBu)-diazomethylketone
    Inhibitor ≥99.0%
    Z-Phe-Tyr(tBu)-diazomethylketone is a potent cathepsin L inhibitor. Z-Phe-Tyr(tBu)-diazomethylketone mediates reovirus disassembly. Z-Phe-Tyr(tBu)-diazomethylketone decreases viral detection.
  • HY-147774
    Cathepsin K inhibitor 6
    Inhibitor 98.18%
    Cathepsin K inhibitor 6 (compound 19) is an inhibitor of cathepsin K (Cat K) with an IC50 of 17 nM. Cathepsin K inhibitor 6 also has inhibitory effects on other isoforms, with IC50s of 0.05 μM (Cat L) and 0.3 μM (Cat B), respectively.
  • HY-152204
    Cathepsin L/S-IN-1
    Inhibitor
    Cathepsin L/S-IN-1 is a dual inhibitor of Cathepsin L and Cathepsin S with IC50s of 4.10 μM and 1.79 μM, respectively. Cathepsin L/S-IN-1 shows a significant antimetastatic and invasive effects on pancreatic cancer BxPC-3 and PANC-1 cells.
  • HY-153614
    Ac-VLPE-FMK
    Inhibitor ≥99.0%
    Ac-VLPE-FMK, a tetrapeptidyl mono-fluoromethyl ketone (m-FMK), is a Cat-B and Cat-L inhibitor. Ac-VLPE-FMK can be used for the research of cancer aggressiveness.
  • HY-152222
    SPR38
    Inhibitor
    SPR38 is a potent SARS-CoV-2 main protease inhibitor, with a Ki of 0.260 μM. SPR38 also inhibits hCatL and hCatB, with Ki values of 1.92 μM and 11.1 μM, respectively.
  • HY-152210
    ASPER-29
    Inhibitor
    ASPER-29 is Asperphenamate HY-129578 analog. ASPER-29 also is a dual cathepsin L and S inhibitor with IC50 value of 6.03 μM and 5.02 μM, respectively. ASPER-29 can be used for the research of the migration and invasion of cancer.
  • HY-P4306
    Z-Phe-Phe-Diazomethylketone
    Inhibitor
    Z-Phe-Phe-Diazomethylketone is a selective inhibitor of cathepsin L.
  • HY-161244
    FGA145
    Inhibitor
    FGA145 is a dual, selective inhibitor for Mpro and human Cathepsin L, with Kis of 3.71 μM, 9.82 μM and 53 nM, for Mal-Mpro, pET21-Mpro and Cathepsin L, respectively. FGA145 reveals a multitarget effects in the antiviral activity.
  • HY-163206
    SARS-CoV-2-IN-77
    Inhibitor
    SARS-CoV-2-IN-77 (compound 11e) is a cathepsin L and cathepsin S inhibitor with Ki values of 111 nM and 103 nM, respectively. SARS-CoV-2-IN-77 inhibits SARS-CoV-2 with an EC50 value of 38.4 nM in Calu-3 cells without showing cytotoxicity.